Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
about
miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression.Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.BH3 Mimetics for the Treatment of Prostate Cancer.Mcl-1 protects prostate cancer cells from cell death mediated by chemotherapy-induced DNA damage.
P2860
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
@ast
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
@en
type
label
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
@ast
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
@en
prefLabel
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
@ast
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
@en
P2093
P2860
P50
P356
P1433
P1476
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
@en
P2093
Birgit Luef
Georg Schäfer
Gertrud E Feiersinger
Helmut Klocker
Iris E Eder
Jayant K Rane
Martina Egger
Su Jung Oh
Zoran Culig
P2860
P304
P356
10.18632/ONCOTARGET.3368
P407
P577
2015-03-01T00:00:00Z